Epigenetic De-repression of PROX1 Promotes Neuroendocrine Prostate Cancer Progression

View Full Paper

Ask AI

Bookmark

Authors

Discussion

CRISPR screening shows PROX1 dependency in neuroendocrine prostate cancer, highlighting its potential as a therapeutic target.

Knockout of prox1 reduced tumor growth in neuroendocrine prostate cancer models, demonstrating its critical role.
CRISPR screening revealed a high dependency on prox1, with implications for targeted therapies in neuroendocrine prostate cancer.
Transcriptomic analyses showed that prox1 regulates neuroendocrine-lineage transcriptional programs in prostate cancer.
Chemical inhibition of CHEK1 and CDK2 decreased NEPC viability, indicating potential therapeutic pathways involving prox1.

Venkadakrishnan et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark